NHS Plans 12-Year Rollout for New Weight-Loss Drug Mounjaro

A novel weight-loss injection is slated for introduction on the NHS in England, but its full distribution to all individuals may extend over 12 years, according to the NHS’s advisory body for medications. The National Institute for Health and Care Excellence (NICE) has issued its final draft guidance for Mounjaro, recommending its administration begin in March, complemented by dietary and exercise advice. Eligibility for the treatment will extend to individuals possessing a body mass index (BMI) exceeding 35 and suffering from at least one health condition linked to obesity, a demographic potentially encompassing 3.4 million people. However, due to apprehensions that the drug’s introduction could strain healthcare services, particularly general practitioners (GPs), NICE has granted the NHS over a decade for its implementation – a decision described as unprecedented for a pharmaceutical product. Professor Jonathan Benger, NICE’s chief medical officer, conceded that this approach would result in “many people would have to wait”. He further stated: “We’ve had to make this difficult decision in order to protect vital NHS services and also to test ways of delivering this new generation of weight-loss medications.” Organizations representing patients have voiced their dissatisfaction regarding the extended timeframe allocated to the NHS for this rollout. Initially, the treatment will be accessible solely to patients already receiving care from specialist weight-management services, mirroring the strategy adopted for Wegovy, a comparable weight-loss medication. Nevertheless, starting in June, the NHS intends to broaden its availability to additional individuals. The precise method of this expansion remains undefined; while general practitioner (GP) practices are expected to manage patient referrals, uncertainty persists regarding the provision of continuous support, including dietary and exercise guidance and monitoring. NHS England is anticipated to release comprehensive guidance on this matter in the new year, potentially incorporating digital applications or the creation of distinct services to assist GPs. Mounjaro, also known as tirzepatide and manufactured by Eli Lilly, functions by inducing a sensation of fullness, thereby reducing food intake. Clinical trials have demonstrated that individuals using the drug experienced an average loss of one-fifth of their body weight. Wegovy, or semaglutide, which is already accessible through the NHS, operates via a comparable mechanism. However, its prescription is currently restricted to patients receiving care from specialist weight-loss management programs. Approximately 40,000 individuals are estimated to fall within this category. These medications are also obtainable through private channels. Furthermore, both drugs are already prescribed for individuals with type 2 diabetes, with semaglutide being sold under the brand name Ozempic for this patient group. The introduction of Mounjaro extends the availability of this new class of weight-loss medications to a broader segment of the population grappling with severe obesity. To qualify, patients must additionally present with at least one obesity-related condition, such as type 2 diabetes, elevated blood pressure, or heart disease. According to the implementation strategy, individuals with the most pressing clinical requirements will receive priority. Projections indicate that approximately 220,000 people will benefit within the initial three-year period. Subsequently, NICE intends to assess the efficacy of this initial phase before proceeding with a more extensive rollout. Given that this constitutes final draft guidance, the rollout could still face delays should any appeals be lodged against the decision. If no appeals are submitted, the guidance is expected to be formally approved before Christmas, as stated by NICE. Mounjaro, administered through weekly injections, will incur a cost of £122 per patient per month for the highest dosage for the NHS; however, NICE has deemed it cost-effective considering the overall expenses associated with obesity. A potential drawback is the risk of weight regain once individuals discontinue the medication. Welsh ministers plan to utilize NICE’s guidance to shape their own implementation strategy. While its use is already endorsed in Scotland, the NHS there is reportedly encountering difficulties with its deployment. Helen Kirrane, representing Diabetes UK, commented that Mounjaro holds a “significant” role in addressing obesity. She further expressed: “We have concerns over the length of time it might take for people to gain access.” Dr. Kath McCullough, NHS England’s national specialty adviser for obesity, characterized weight-loss medications as an “important tool” in confronting “one of the greatest public health issues facing the NHS”. She explained that the staggered implementation was necessary to safeguard patient access to other essential NHS services. Moreover, Professor Kamila Hawthorne from the Royal College of GPs cautioned against viewing the drug as a “silver bullet,” emphasizing that it carries inherent risks and may not be the appropriate treatment for all eligible individuals.